Mesoblast Limited vs PayPal Holdings, Inc. — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while PayPal Holdings, Inc. trades at $55.97 (market cap $50.12B). The key difference: PayPal Holdings, Inc. is far larger — about 23.1× Mesoblast Limited's market cap, and PayPal Holdings, Inc. pays a 0.99% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PYPL | |
|---|---|---|
Market Cap | $2.17B | $50.12B |
Sector | Technology | Financials |
52-Week High | $20.96 | $78.22 |
52-Week Low | $12.88 | $39.08 |
Enterprise Value | $2.17B | $50.19B |
Dividend Yield | — | 0.99% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
PayPal (PYPL) trades at $56.78, up 0.38% with strong technical momentum as the stock approaches resistance near $57-$59 following a $53 billion takeover bid from Stripe and Advent International. The company shows solid fundamentals with 2025 revenue of $33.17B, net income of $5.23B (15% margin), and attractive valuation metrics including a P/E of 10.6 and P/S of 1.6. Recent earnings beat expectations in Q1 2026 with EPS of $1.34 versus $1.27 expected.
The acquisition offer at $60.50 per share provides near-term upside potential, though the board considers it undervalued. Key risks include regulatory hurdles for the deal and competitive pressures in digital payments. Analyst sentiment is mixed with 36% buy ratings but a consensus price target of $50.80 below current levels, suggesting cautious optimism amid takeover speculation.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →